Gilead gets big order after announcement on remdesivir

30 June 2020

As Gilead Sciences (Nasdaq: GILD) revealed the price of remdesivir, its antiviral treatment for COVID-19, the US government announced that it has got its hands on another huge batch of the drug.

This adds to the 120,000 treatment courses that have been donated to the USA by Gilead.

The Department of Health and Human Services (HHS) announced the agreement to secure large supplies of the drug from Gilead for the USA through September on Monday, allowing American hospitals to purchase it in amounts allocated by the HHS and state health departments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK